Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Dyslipidaemia : Update Bulletin [December 2016]

Product Code:
596200542
Publication Date:
December 2016
Format:
PDF
Price:
$1,045

Gain new KOL insights on the latest events happening in dyslipidaemia: Pfizer’s discontinuation of the development of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, bococizumab, and its Phase III SPIRE programme; the Medicines Company’s progress update from the Phase II ORION-1 study of inclisiran (ALN-PCSsc), its investigational first-in-class RNA interference (RNAi) oligonucleotide directed against PCSK9, licensed from Alnylam; and progress on Esperion Therapeutics’ global Phase III (CLEAR) programme for bempedoic acid (ETC-1002), a first-in-class ATP citrate lyase (ACL) inhibitor.

Highlights from this event update bulletin

  • How will termination of Pfizer’s SPIRE development programme for bococizumab impact the PCSK9 inhibitor field?
  • What are KOL’s expecting from the impending Repatha and Praluent outcomes studies?
  • What are KOL’s reactions to Medicines Company’s Phase II ORION-1 study of inclisiran (ALN-PCSsc)?
  • What is expected from the Medicines Company’s inclisiran in terms of efficacy and safety?
  • Could the novel RNAi therapy, inclisiran, supplant statins in first-line?
  • How is twice-yearly inclisiran likely to be priced, and what do KOLs suggest for wider acceptance?
  • What do KOLs think of Esperion Therapeutics’ ACL inhibitor, bempedoic acid?
  • Where is bempedoic acid likely to fit in the treatment strategy and how will it impact current options?
  • How will the pricing of these various agents impact KOL prescribing behaviour?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.




customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved